IMAB
- I-Mab
()
Overview
Company Summary
I-Mab, also known by its ticker symbol IMAB, is a biotechnology company that focuses on the discovery, development, and commercialization of innovative drugs targeting unmet medical needs.
The company primarily operates in the field of immuno-oncology, which involves leveraging the body's immune system to fight cancer. I-Mab develops monoclonal antibodies and small molecules that specifically target cancer cells, preventing their growth, or enhancing the immune system's ability to identify and eliminate tumors.
One of I-Mab's key areas of expertise is the development of bi-specific antibodies, which have the ability to simultaneously bind to two different targets. These therapies can strategically engage the immune system while directly impacting tumor cells for more efficient and targeted treatment of cancer.
In addition to immuno-oncology, I-Mab also has programs focused on treating autoimmune diseases and other immune-related disorders. The company's pipeline includes potential treatments for diseases such as rheumatoid arthritis, lupus nephritis, and multiple sclerosis. Through their research and development efforts, I-Mab aims to create innovative therapies that can improve patients' quality of life and provide effective treatment options for individuals suffering from these debilitating conditions.
Overall, I-Mab's mission is to advance the field of biotechnology by developing novel therapies that harness the power of the immune system to target and combat various diseases, with a particular focus on cancer and autoimmune disorders.